Cargando…
Dolutegravir for second-line treatment: Programmatic implications of new evidence
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AOSIS
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559621/ https://www.ncbi.nlm.nih.gov/pubmed/36299553 http://dx.doi.org/10.4102/sajhivmed.v23i1.1428 |
| _version_ | 1784807676079767552 |
|---|---|
| author | Zhao, Ying Maartens, Gary Meintjes, Graeme |
| author_facet | Zhao, Ying Maartens, Gary Meintjes, Graeme |
| author_sort | Zhao, Ying |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9559621 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AOSIS |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95596212022-10-25 Dolutegravir for second-line treatment: Programmatic implications of new evidence Zhao, Ying Maartens, Gary Meintjes, Graeme South Afr J HIV Med Editorial AOSIS 2022-09-05 /pmc/articles/PMC9559621/ /pubmed/36299553 http://dx.doi.org/10.4102/sajhivmed.v23i1.1428 Text en © 2022. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License. |
| spellingShingle | Editorial Zhao, Ying Maartens, Gary Meintjes, Graeme Dolutegravir for second-line treatment: Programmatic implications of new evidence |
| title | Dolutegravir for second-line treatment: Programmatic implications of new evidence |
| title_full | Dolutegravir for second-line treatment: Programmatic implications of new evidence |
| title_fullStr | Dolutegravir for second-line treatment: Programmatic implications of new evidence |
| title_full_unstemmed | Dolutegravir for second-line treatment: Programmatic implications of new evidence |
| title_short | Dolutegravir for second-line treatment: Programmatic implications of new evidence |
| title_sort | dolutegravir for second-line treatment: programmatic implications of new evidence |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559621/ https://www.ncbi.nlm.nih.gov/pubmed/36299553 http://dx.doi.org/10.4102/sajhivmed.v23i1.1428 |
| work_keys_str_mv | AT zhaoying dolutegravirforsecondlinetreatmentprogrammaticimplicationsofnewevidence AT maartensgary dolutegravirforsecondlinetreatmentprogrammaticimplicationsofnewevidence AT meintjesgraeme dolutegravirforsecondlinetreatmentprogrammaticimplicationsofnewevidence |